Kevin is an Engagement Manager at HTAnalysts with a strong background in pharmaceutical reimbursement, health economic modelling and reimbursement strategy.
Kevin joined HTAnalysts in October 2018 as an Engagement Manager. Kevin has expertise in market access and pharmaceutical reimbursement strategies, with a strong understanding of PBS policy. During his time at HTAnalysts, he has managed and contributed to several reimbursement submissions including co-dependent submissions to the PBAC and PHARMAC. His involvement has ranged from conducting early-stage feasibility assessments to devising submission strategy including leading budget impact and economic modelling. Kevin has also been involved in the development of clinical practice guidelines, systematic review and meta-analyses, and health technology due diligence assessment. Kevin has experience across numerous therapeutic areas including oncology, precision medicine, ophthalmology, obstetrics, neurology and immunology. He has also made significant contributions to numerous conference abstracts and scientific manuscripts.
Prior to joining HTAnalysts, Kevin worked as a market access intern at AbbVie Australia where he made substantial contributions and led sections for PBAC and PHARMAC submissions, including the development of budget impact models. He was also heavily involved in pricing, feasibility, and biosimilar impact assessments whilst working across the immunology, oncology and specialty care portfolios and gastroenterology brand team.
Kevin holds a Bachelor of Biomedical Science from Monash University and is currently studying a Master of Biostatistics at Monash University. He is proficient in TreeAge and Microsoft Excel and has a strong understanding of statistical packages such as R and STATA.